Analysts Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $25.14

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have earned a consensus rating of "Buy" from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $25.14.

Several analysts have weighed in on IMNM shares. Guggenheim lowered their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Lake Street Capital initiated coverage on Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price target on the stock. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective for the company. Wedbush restated an "outperform" rating and issued a $33.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Stephens reissued an "overweight" rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th.

Insider Buying and Selling at Immunome

In other news, CTO Philip Tsai acquired 12,300 shares of the firm's stock in a transaction on Monday, March 24th. The stock was acquired at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the acquisition, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. This trade represents a 58.57 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Clay B. Siegall bought 150,000 shares of the company's stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This represents a 28.87 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 306,400 shares of company stock valued at $2,322,995. 8.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in Immunome in the fourth quarter worth about $70,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Immunome in the 4th quarter worth approximately $75,000. AlphaQuest LLC increased its position in Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after buying an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after buying an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Immunome in the fourth quarter worth $95,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Trading Down 4.5 %

Shares of NASDAQ:IMNM traded down $0.28 during trading on Friday, reaching $5.93. The company had a trading volume of 331,620 shares, compared to its average volume of 889,324. Immunome has a 12 month low of $5.15 and a 12 month high of $21.72. The stock has a market capitalization of $515.53 million, a P/E ratio of -0.73 and a beta of 2.05. The company has a fifty day moving average of $8.72 and a two-hundred day moving average of $10.71.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, equities research analysts predict that Immunome will post -2.21 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.